- Home
- SEPN vs RGNX Comparison
SEPN vs RGNX Comparison
Compare SEPN & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEPN
- RGNX
- Stock Information
- Founded
- SEPN 2022
- RGNX 2008
- Country
- SEPN United States
- RGNX United States
- Employees
- SEPN 75
- RGNX N/A
- Industry
- SEPN
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SEPN
- RGNX Health Care
- Exchange
- SEPN NYSE
- RGNX Nasdaq
- Market Cap
- SEPN 553.0M
- RGNX 424.8M
- IPO Year
- SEPN 2024
- RGNX 2015
- Fundamental
- Price
- SEPN $12.21
- RGNX $8.19
- Analyst Decision
- SEPN Strong Buy
- RGNX Strong Buy
- Analyst Count
- SEPN 5
- RGNX 8
- Target Price
- SEPN $26.75
- RGNX $31.75
- AVG Volume (30 Days)
- SEPN 222.3K
- RGNX 579.8K
- Earning Date
- SEPN 08-15-2025
- RGNX 08-07-2025
- Dividend Yield
- SEPN N/A
- RGNX N/A
- EPS Growth
- SEPN N/A
- RGNX N/A
- EPS
- SEPN N/A
- RGNX N/A
- Revenue
- SEPN $977,000.00
- RGNX $156,718,000.00
- Revenue This Year
- SEPN $3,429.67
- RGNX $327.08
- Revenue Next Year
- SEPN N/A
- RGNX N/A
- P/E Ratio
- SEPN N/A
- RGNX N/A
- Revenue Growth
- SEPN 108.76
- RGNX 80.70
- 52 Week Low
- SEPN $4.17
- RGNX $5.04
- 52 Week High
- SEPN $28.99
- RGNX $15.02
- Technical
- Relative Strength Index (RSI)
- SEPN N/A
- RGNX 43.67
- Support Level
- SEPN N/A
- RGNX $8.27
- Resistance Level
- SEPN N/A
- RGNX $9.32
- Average True Range (ATR)
- SEPN 0.00
- RGNX 0.50
- MACD
- SEPN 0.00
- RGNX -0.03
- Stochastic Oscillator
- SEPN 0.00
- RGNX 12.40
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.